Trial Profile

Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Micafungin (Primary)
Indications Invasive candidiasis; Nosocomial infections; Sepsis
Focus Therapeutic Use
Acronyms EMPIRICUS

Most Recent Events

05 Oct 2016 Primary endpoint has not been met, (survival to 28 days without proven fungal infection (a fungal infection occurring within 48 hours after inclusion will be considered available for inclusion)), according to the results published.
05 Oct 2016 Results (n=260) published in the JAMA: the Journal of the American Medical Association.
23 Mar 2015 Status changed from recruiting to completed as reported by Clinicaltrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com